# CRISPR Therapeutics

史上首个CRISPR药物，2023年12月FDA批准SCD，2024年1月批准TDT；美国≥12岁约1000名患者符合治疗条件；儿科sNDA 2026年审查中。

Source: https://cn.bioecon.ru/companies/crispr-therapeutics/
Updated: 2026-06-24

- 国家: Switzerland
- 代码: CRSP

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 截至2025年12月31日，公司持有现金、现金等价物及有价证券$19.758亿。公司历史上持续亏损，仍需追加资本。 | https://crisprtx.gcs-web.com/static-files/758a3569-9792-4af2-a773-f5e71afea36a, https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/R12.htm |
| 生产基地 | 位于马萨诸塞州Framingham的全资GMP生产设施。 | https://crisprtx.com/who-we-are, https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14, https://crisprtx.gcs-web.com/static-files/758a3569-9792-4af2-a773-f5e71afea36a, https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7, https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/R12.htm |
| 产能 | 为其细胞治疗产品组合提供端到端生产能力，支持临床与商业化供应。 | https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14, https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7 |
| 监管批准 | FDA于2023年12月批准CASGEVY用于SCD与TDT（12岁及以上），并于2026年批准用于2岁及以上儿童。 | https://ir.crisprtx.com/static-files/156e1fc1-277c-4ac7-a514-e90aa850a294, https://last10k.com/sec-filings/crsp/0001193125-26-330672.htm, https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease |
| 员工人数 | 截至2026年年中，估计员工约介于304至393名之间。 [中等置信度] | https://altindex.com/ticker/crsp/employees-linkedin, https://profit.com/ticker/CRSP/profile |
| 营收 | 报告2026年第二季度收入$7600万，2025全年$1.16亿。 | https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14, https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7, https://last10k.com/sec-filings/crsp/0001193125-26-330672.htm |

独立来源: altindex.com, crisprtx.com, crisprtx.gcs-web.com, fda.gov, ir.crisprtx.com, last10k.com, pmc.ncbi.nlm.nih.gov, profit.com, sec.gov

## 技术

- [个性化与再生医学](https://cn.bioecon.ru/technology/personalized-regenerative-medicine/)
- [基因组编辑](https://cn.bioecon.ru/technology/genome-editing/)